ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1899

Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States
Abstract Number: 1900

Assessment of Hospitalist Confidence Levels in Management of Rheumatic Conditions to Identify Potential Knowledge Gaps
Abstract Number: 1901

Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration
Abstract Number: 1902

Improving the Sharing of Information from Reviews of Measurement Properties: The OMERACT Summary of Measurement Properties (SOMP) Table
Abstract Number: 1903

Assessing Disparities Through Missing Race and Ethnicity Data: Results from a Juvenile Arthritis Registry
Abstract Number: 1904

Treat-to-Target in RA Clinical Practice: Global Evidence of Practice Gaps and Educational Needs
Abstract Number: 1905

Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic
Abstract Number: 1906

Implementation Practices for the 2022 American College of Rheumatology Guidelines for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis
Abstract Number: 1907

Selection of a Candidate Instrument to Assess Flare in Osteoarthritis with Content Matching with Endorsed Domains
Abstract Number: 1908

Clinic Protocol Boosts Blood Pressure Confirmatory Readings and Accuracy in an Academic Medical Center
Abstract Number: 1909

Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease
Abstract Number: 1910

Development of the American College of Rheumatology Toolkit for Implementation of Rheumatoid Arthritis Outcome Measures in Clinical Practice
Abstract Number: 1911

Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study
Abstract Number: 1912

Impact of Pharmacist-Led Specialty Medication Management Service on Time-to-Dispense for Specialty Rheumatologic Medications in a University Health System
Abstract Number: 1913

Neurosarcoidosis Disease Epidemiology. University Hospital in Northern Spain 1999-2019

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].